ClinicalTrials.gg
TerminatedNCT00957580Updated Aug 21, 2017Results posted

Trial of Pimasertib in Hematological Malignancies

A Phase 2 interventional study of Pimasertib and Pimasertib in Leukemia, Myeloid, Acute and Hematologic Neoplasms, sponsored by EMD Serono. Terminated at 9 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-08-21.

Sponsored by EMD Serono (part of Merck KGaA, Darmstadt, Germany) · Phase 2, Interventional, and Treatment

Why this study was terminated
The trial has been terminated due to an estimated low probability of clinical benefit based on limited anti-leukemic effects observed in safety run-in (Part 1)

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
81
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 2,137 studies in Leukemia, Myeloid, Acute with a site in United States — 312 open to participants now, 466 under way, 24 of them phase 3. Leukemia, Myeloid, Acute · United States.

Enrollment
403rd of 1,907
81 · median 35
Started
2009
with 74 others
Phase 2
647 of 2,137
75 open now
Registered
667th of 2,137
by date

Among the 2,137 studies in Leukemia, Myeloid, Acute with a site in United States, this one is the 403rd largest by enrollment of the 1,907 interventional ones that give a count, is one of 75 that started in 2009, is one of 647 in phase 2, and was the 667th registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

312 of the 2,137 studies in Leukemia, Myeloid, Acute with a site in United States are open now. Recruiting first, the newest first:

307 more — sign in →

All 312 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,137 studies in Leukemia, Myeloid, Acute with a site in United States, or all of them as a file.
02

Study summary

This is an open-label, multi-center, dose-escalation trial of pimasertib (MSC1936369B) in blood and bone marrow cancers. The trial will be conducted in two parts:

Part 1 (safety run-in period): Will determine the maximum tolerated dose (MTD) of the study drug in subjects with advanced hematological malignancies.

Part 2: Will assess the anti-leukemic activity of the study drug in older subjects with newly diagnosed poor prognosis acute myeloid leukemia (AML) who are not candidates for intensive chemotherapy.

03

Conditions studied

  • Leukemia, Myeloid, Acute
  • Hematologic Neoplasms

Keywords

  • MEK Inhibitor
  • Pimasertib
  • Acute Myeloid Leukemia
  • Hematological Malignancies
  • Elderly Patients
  • Phase II
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Part 1:

  1. Subjects with one of the following conditions:

    • Primary or secondary AML, confirmed according to World Health Organization (WHO) classification who meet at least one of the following conditions:

      1. Subjects with second or subsequent relapse after standard therapy, for whom no established treatment options are available
      2. Subjects to available therapies, for example, who failed to achieve complete response (CR) after 2 induction chemotherapy treatments
      3. Newly-diagnosed older subjects (greater than or equal to 75 years of age), not candidates for intensive chemotherapy
    • Subjects with myelodysplastic syndrome (MDS), International Prognostic Scoring System (IPSS) Int-2 or high risk who are resistant or intolerant to standard treatment and not candidates for transplantation
    • Subjects with relapsed or refractory multiple myeloma (MM), who have failed or are intolerant to at least two prior therapies including thalidomide, lenalidomide and bortezomib
    • Subjects with advanced myeloproliferative disorders (MPD) for whom no established treatment options are available
    • Subjects with acute lymphocytic leukemia (ALL), relapsed, refractory or intolerant to standard treatment and for whom no effective treatment options are available
  2. Age greater than or equal to 18 years
  3. Subjects have read and understood the Form and are willing and able to give informed consent. They fully understand requirements of the trial and are willing to comply with all trial visits and assessments
  4. Subjects and their partners must be willing to avoid pregnancy during the trial and until 1 month after the last trial drug administration. Subjects must therefore be willing to use adequate as approved by the Investigator, two barrier methods or one barrier method with spermicide or intrauterine device, 2 weeks before, during the trial and 1 month after. The use of hormonal contraceptives should be avoided due to a possible drug-drug interaction in female subjects of childbearing age

Part 2:

  1. Subjects (male and female) with newly diagnosed primary or secondary AML pathologically confirmed according to WHO classification who have not been exposed to any prior therapy for AML with the exception of:

    • Emergency leukapheresis and
    • Emergency treatment for hyperleukocytosis with hydroxyurea that is allowed until 24 hours before the start of the trial treatment. Prior therapy for pre-existing hematological conditions, for example, MDS or MPD, including but not limited to hypomethylating agents, is also allowed until at least 2 weeks or 5 half-lives of that agent before the first dose of pimasertib
  2. Subjects meet at least one of the following conditions:

    • Age greater than or equal to 75 years OR
    • Age greater than or equal to 60 and less than 75 years with at least one of the following poor prognostic factors:

      • Secondary AML, as determined by known and documented exposure to leukemogenic therapy or environmental toxin or antecedent history of MDS or MPD according to WHO criteria for at least 3 months prior to trial entry, with prior bone marrow aspirate, and peripheral blood smear documenting the diagnosis
      • At least one of the following unfavorable cytogenetic abnormalities: del(5q), -5, -7, del(7q), abn 3q, 9q, 11q, 20q, 21q, 17p, t(6;9), t(9;22) or complex karyotypes (greater than or equal to 3 unrelated abnormalities)
      • (ECOG) status 2
  3. Subjects have read and understood the Informed Consent Form and are willing and able to give informed consent. They fully understand requirements of the trial and are willing to comply with all trial visits and assessments
  4. Subjects and their partners must be willing to avoid pregnancy during the trial and until 1 month after the last trial drug administration. Subjects must therefore be willing to use adequate contraception as approved by the Investigator such as two barrier methods or one barrier method with spermicide or intrauterine device, 2 weeks before, during the trial and 1 month after. The use of hormonal contraceptives should be avoided due to a possible drug-drug interaction in female subjects of childbearing age

Exclusion criteria

Exclusion Criteria:

Part 1 and Part 2:

  1. performance status 3 or greater
  2. Hyperleukocytosis with greater than 30 x 10 to the ninth power per liter leukemia blasts in peripheral blood
  3. Acute promyelocytic leukemia [t(15;17)]
  4. Administration of any antineoplastic therapy within at least 2 weeks or 5 half lives of that therapy of the first pimasertib dose; except the use of hydroxyurea as permitted in inclusion criteria
  5. Participation in other clinical trials within at least 2 weeks of the first pimasertib dose
  6. Clinical evidence of active central nervous system leukemia
  7. Active and uncontrolled infection including but not limited to known infection with (HIV), active or . Subjects with an infection receiving treatment with antibiotics may be entered into the trial if they are afebrile and hemodynamically stable for 48 hours prior to trial entry
  8. Major surgery within two weeks prior to trial entry
  9. Liver function tests above the following limits at screening: total >1.5 x (ULN) unless related to Gilbert's syndrome or hemolysis, (AST) and/or alanine aminotransferase (ALT) >2.5 x ULN, or for subjects with liver involvement AST and/or ALT >5 x ULN
  10. Serum creatinine >1.5 x ULN and /or \<30 milliliter per minute (mL/min) at screening
  11. (INR) greater than 1.5 x ULN unless on treatment with warfarin
  12. For female subjects: pregnant or breast-feeding
  13. History of difficulty swallowing, malabsorption or other chronic gastro-intestinal disease or conditions that may hamper compliance and/or absorption of the tested product
  14. Has significant cardiac conduction abnormalities and/or pacemaker
  15. Has retinal degenerative disease (heredity retinal degeneration or age-related macular degeneration), history of uveitis or history of retinal vein occlusion and/or any medically relevant abnormal findings at the initial ophthalmologic examination
  16. Subjects with solid tumors, for whom the Investigator has clinical suspicion of active disease at the time of enrolment. Subjects with adequately treated early stage squamous cell carcinoma of the skin, basal cell carcinoma of the skin, or cervical intraepithelial neoplasia (CIN) are eligible for this study
  17. Signs and symptoms suggestive of transmissible spongiform encephalopathy, or family members who suffer(ed) from such
  18. Other significant disease that in the Investigator's opinion would exclude the subject from the trial
  19. Legal incapacity or limited legal capacity
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
81 participants (actual)

Study arms

  • Experimental
    Regimen 1 (Part 1)

    Drug: Pimasertib

  • Experimental
    Regimen 2 (Part 1)

    Drug: Pimasertib

  • Experimental
    Regimen 3 (Part 1)

    Drug: Pimasertib

  • Experimental
    Regimen 1 (Part 2)

    Drug: Pimasertib

  • Experimental
    Regimen 2 (Part 2)

    Drug: Pimasertib

Interventions

  • Pimasertib will be administered orally at a dose of 8 mg twice daily (BID) on Days 1 to 5, 8 to 12, 15 to 19, and 22 to 26 of a 28-day cycle. The dose will be escalated to 15 mg BID, 23 mg BID, 30 mg BID, 42 mg BID, 60 mg BID, and 75 mg BID) until Maximum Tolerated Dose (MTD) is reached. The treatment will be continued until disease progression, intolerable toxicity, or Investigator/subject decision.

    Also known as: MSC1936369B

  • Pimasertib will be administered orally at a dose of 8 mg BID on Days 1 to 21 of a 28-day cycle. The dose will be escalated to 15 mg BID, 23 mg BID, 30 mg BID, 42 mg BID, 45 mg BID, 60 mg BID, 75 mg BID, and 90 mg BID until MTD is reached. The treatment will be continued until disease progression, intolerable toxicity, or Investigator/subject decision.

    Also known as: MSC1936369B

  • Pimasertib will be administered orally at a dose of 60 mg BID on Days 1-28 of a 28-day cycle. The dose escalation will proceed to 75 mg BID until MTD is reached. The treatment will be continued until disease progression, intolerable toxicity, or Investigator/subject decision.

    Also known as: MSC1936369B

  • Pimasertib will be administered orally twice daily on Days 1 to 5, 8 to 12, 15 to 19, and 22 to 26 of a 28-day cycle. Dose will be determined by Part 1 of the trial (could be the MTD or lower dose level). The treatment will be continued until disease progression, intolerable toxicity, or Investigator/subject decision.

    Also known as: MSC1936369B

  • Pimasertib will be administered orally twice daily on Days 1 to 21 of a 28-day cycle. Dose will be determined by Part 1 of the trial (could be the MTD or lower dose level). The treatment will be continued until disease progression, intolerable toxicity, or Investigator/subject decision.

    Also known as: MSC1936369B

06

What researchers measure

Primary outcomes

  1. Part 1: Number of Subjects With Dose Limiting Toxicities (DLTs)

    The DLT was any toxicity that resulted in treatment delay for more than (\>) 2 weeks due to treatment-related adverse effects, or any Grade greater than or equal to (\>=) 3 non-hematological toxicity excluding Grade 4 asymptomatic increases in liver function tests reversible within 7 days in subjects with liver involvement, and Grade 3 asymptomatic increases in liver function tests reversible within 7 days for subjects without liver involvement, Grade 3 vomiting unless encountered and persistent for more than 3 days despite adequate and optimal therapy, and Grade 3 diarrhea unless encountered and persistent for more than 3 days despite adequate and optimal anti-diarrhea therapy at any DL and judged to be possibly or probably related to the trial treatment by the Investigator and/or the Sponsor.

    Time frame: Baseline Up to Day 29 of Cycle 1

  2. Part 2: Percentage of Subjects With Best Overall Response

    The best overall response was to be reported as either of the following: (1) Morphologic complete remission (CR) = normalization of the peripheral blood absolute neutrophil count (PBANC) \>1.0x10\^9 per liter (/L), platelets \>100x10\^9 /L, bone marrow aspirate with less than or equal to (\<=) 5 percent (%) blasts, no blasts with Auer rods (AML only). (2) Complete remission with incomplete blood count recovery (CRi) = Same as CR without normalization of PBANC and platelet count. (3) Partial remission (PR) = normalization of PBANC \>1.0x10\^9/L, platelets \>100x10\^9/L, and at least a 50% decrease in the percentage of marrow aspirate blasts to 5-25%, or marrow blasts less than (\<) 5%. (4) Progressive disease (PD) = \>50% increase in peripheral blood or bone marrow blasts. (5) Stable disease (SD) = subjects who failed to achieve CR, CRi or PR and without criteria for PD.

    Time frame: Day 29 of every 29-day cycle until progression reported between day of first subject randomized, September 2009, until cut-off date, December 2012

Secondary outcomes

  1. Part 1: Number of Subjects With Treatment-emergent Adverse Events (TEAEs), Serious TEAEs, TEAEs Leading to Death and TEAEs Leading to Permanent Treatment Discontinuation

    An adverse event (AE) was defined as any new untoward medical occurrences/worsening of pre-existing medical condition, whether or not related to study drug. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect. TEAEs include both SAEs and non-SAEs.

    Time frame: Baseline up to 3 years

  2. Part 1: Maximum Plasma Concentration (Cmax) of Pimasertib Single Dose

    Time frame: Predose 0.5, 1.0, 1.5, 2.0, 2.5, 4.0, 6.0, and 10.0 hours post-dose on Day 1 of cycle 1; Regimen 1, 2 and 3

  3. Part 1: Maximum Plasma Concentration (Cmax) of Pimasertib Multiple Dose

    Time frame: Pre dose 0.5, 1.0, 1.5, 2.0, 2.5, 4.0, 6.0, and 10.0 hours post dose in Cycle 1 on Day 19 to Day 21 (Regimen 1 and 2) or Day 26 (Regimen 3).

  4. Part 1: Time to Reach Maximum Plasma Concentration (Tmax): Single Dose

    Time frame: Predose 0.5, 1.0, 1.5, 2.0, 2.5, 4.0, 6.0, and 10.0 hours post-dose on Day 1 of cycle 1; Regimen 1, 2 and 3

  5. Part 1: Time to Reach Maximum Plasma Concentration (Tmax): Multiple Dose

    Time frame: Pre dose 0.5, 1.0, 1.5, 2.0, 2.5, 4.0, 6.0, and 10.0 hours post dose in Cycle 1 on Day 19 to Day 21 (Regimen 1 and 2) or Day 26 (Regimen 3)

  6. Part 1: Apparent Terminal Half-Life (t1/2) of Pimasertib: Single Dose

    The apparent terminal half-life was defined as the time required for the plasma concentration of drug to decrease 50% in the final stage of its elimination.

    Time frame: Predose 0.5, 1.0, 1.5, 2.0, 2.5, 4.0, 6.0, and 10.0 hours post-dose on Day 1 of cycle 1; Regimen 1, 2 and 3

  7. Part 1: Apparent Terminal Half-Life (t1/2) of Pimasertib: Multiple Dose

    The apparent terminal half-life was defined as the time required for the plasma concentration of drug to decrease 50% in the final stage of its elimination.

    Time frame: Pre dose 0.5, 1.0, 1.5, 2.0, 2.5, 4.0, 6.0, and 10.0 hours post dose in Cycle 1 on Day 19 to Day 21 (Regimen 1 and 2) or Day 26 (Regimen 3).

  8. Part 1: Area Under Curve From Time Zero to Last Sampling Time at Which the Concentration is at or Above Lower Limit of Quantification (AUC0-t) of Pimasertib: Single Dose

    Time frame: Predose 0.5, 1.0, 1.5, 2.0, 2.5, 4.0, 6.0, and 10.0 hours post-dose on Day 1 of cycle 1; Regimen 1, 2 and 3

  9. Part 1: Area Under Curve From Time Zero to Last Sampling Time at Which the Concentration is at or Above Lower Limit of Quantification (AUC0-t) of Pimasertib: Multiple Dose

    Time frame: Pre dose 0.5, 1.0, 1.5, 2.0, 2.5, 4.0, 6.0, and 10.0 hours post dose in Cycle 1 on Day 19 to Day 21 (Regimen 1 and 2) or Day 26 (Regimen 3).

  10. Part 1: Area Under Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Pimasertib: Single Dose

    The AUC0-inf was estimated by determining the total area under the curve of the concentration versus time curve extrapolated to infinity. It is obtained from AUC0-t plus AUCt-infinity.

    Time frame: Predose 0.5, 1.0, 1.5, 2.0, 2.5, 4.0, 6.0, and 10.0 hours post-dose on Day 1 of cycle 1; Regimen 1, 2 and 3

  11. Part 1: Area Under Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Pimasertib: Multiple Dose

    The AUC0-inf was estimated by determining the total area under the curve of the concentration versus time curve extrapolated to infinity. It is obtained from AUC0-t plus AUCt-infinity.

    Time frame: Pre dose 0.5, 1.0, 1.5, 2.0, 2.5, 4.0, 6.0, and 10.0 hours post dose in Cycle 1 on Day 19 to Day 21 (Regimen 1 and 2) or Day 26 (Regimen 3)

  12. Part 1: Apparent Oral Clearance (CL/f) of Pimasertib: Single Dose

    Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Apparent clearance after oral dose (CL/f) is influenced by the fraction absorbed. Data for Pimasertib 75 mg arm was not available for all the regimens combined, thus reported as separate outcome measure and not included in this outcome.

    Time frame: Predose 0.5, 1.0, 1.5, 2.0, 2.5, 4.0, 6.0, and 10.0 hours post-dose on Day 1 of cycle 1; Regimen 1, 2 and 3

  13. Part 1: Apparent Oral Clearance (CL/f) of Pimasertib for Pimasertib 75 mg Reporting Arm: Single Dose

    Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Apparent clearance after oral dose (CL/f) is influenced by the fraction absorbed.

    Time frame: Predose 0.5, 1.0, 1.5, 2.0, 2.5, 4.0, 6.0, and 10.0 hours post-dose on Day 1 of cycle 1; Regimen 1, 2 and 3

  14. Part 1: Apparent Oral Clearance (CL/f) of Pimasertib: Multiple Dose

    Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Apparent clearance after oral dose (CL/f) is influenced by the fraction absorbed.

    Time frame: Pre dose 0.5, 1.0, 1.5, 2.0, 2.5, 4.0, 6.0, and 10.0 hours post dose in Cycle 1 on Day 19 to Day 21 (Regimen 1 and 2) or Day 26 (Regimen 3)

  15. Part 1: Apparent Oral Volume of Distribution (Vz/f) of Pimasertib:Single Dose

    Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. Apparent volume of distribution after oral dose (Vz/f) was influenced by the fraction absorbed. Data for Pimasertib 75 mg arm was not available for all the regimens combined, thus reported as separate outcome measure and not included in this outcome.

    Time frame: Predose 0.5, 1.0, 1.5, 2.0, 2.5, 4.0, 6.0, and 10.0 hours post-dose on Day 1 of cycle 1; Regimen 1, 2 and 3

  16. Part 1: Apparent Oral Volume of Distribution (Vz/f) of Pimasertib for Pimasertib 75 mg Reporting Arm:Single Dose

    Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. Apparent volume of distribution after oral dose (Vz/f) was influenced by the fraction absorbed.

    Time frame: Predose 0.5, 1.0, 1.5, 2.0, 2.5, 4.0, 6.0, and 10.0 hours post-dose on Day 1 of cycle 1; Regimen 1, 2 and 3

  17. Part 1: Apparent Oral Volume of Distribution (Vz/f) of Pimasertib: Multiple Dose

    Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. Apparent volume of distribution after oral dose (Vz/f) was influenced by the fraction absorbed.

    Time frame: Pre dose 0.5, 1.0, 1.5, 2.0, 2.5, 4.0, 6.0, and 10.0 hours post dose in Cycle 1 on Day 19 to Day 21 (Regimen 1 and 2) or Day 26 (Regimen 3)

  18. Part 1: Percentage of Subjects With Best Overall Response

    The best overall response was reported as either of the following: (1) Morphologic complete remission (CR) = normalization of the peripheral blood absolute neutrophil count (PBANC) \>1.0x10\^9 per liter (/L), platelets \>100x10\^9 /L, bone marrow aspirate with less than or equal to (\<=) 5 percent (%) blasts, no blasts with Auer rods (AML only). (2) Complete remission with incomplete blood count recovery (CRi) = Same as CR without normalization of PBANC and platelet count. (3) Partial remission (PR) = normalization of PBANC \>1.0x10\^9/L, platelets \>100x10\^9/L, and at least a 50% decrease in the percentage of marrow aspirate blasts to 5-25%, or marrow blasts less than (\<) 5%. (4) Progressive disease (PD) = \>50% increase in peripheral blood or bone marrow blasts. (5) Stable disease (SD) = Subjects who failed to achieve CR, CRi or PR and without criteria for PD.

    Time frame: Day 29 of every alternate 29-day cycle until progression reported between day of first subject randomized, September 2009, until cut-off date, December 2012

  19. Part 2: Number of Subjects With TEAEs, Serious TEAEs, TEAEs Leading to Death and TEAEs Leading to Permanent Treatment Discontinuation

    An adverse event (AE) was defined as any new untoward medical occurrences/worsening of pre-existing medical condition, whether or not related to study drug. A serious adverse event (SAE) was an AE that results in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect.

    Time frame: Up to 3 years

07

Results

Posted Mar 29, 2017
Limitations and caveats
The trial has been terminated due to an estimated low probability of clinical benefit based on limited anti-leukemic effects observed in safety run-in (Part 1).

Participant flow

First/last subject (informed consent): September 2009/12 April 2012. Last subject completed : December 2012; Clinical data cut-off: December 2012.

Participant flow — Overall Study
MilestoneRegimen 1 (Part 1)Regimen 2 (Part 1)Regimen 3 (Part 1)
Started333315
Treated333215
Completed333115
Not completed020
Withdrew: Ongoing at data cut-off010
Withdrew: Enrolled but not treated010

Outcome measures

PrimaryPart 1: Number of Subjects With Dose Limiting Toxicities (DLTs)

The DLT was any toxicity that resulted in treatment delay for more than (\>) 2 weeks due to treatment-related adverse effects, or any Grade greater than or equal to (\>=) 3 non-hematological toxicity excluding Grade 4 asymptomatic increases in liver function tests reversible within 7 days in subjects with liver involvement, and Grade 3 asymptomatic increases in liver function tests reversible within 7 days for subjects without liver involvement, Grade 3 vomiting unless encountered and persistent for more than 3 days despite adequate and optimal therapy, and Grade 3 diarrhea unless encountered and persistent for more than 3 days despite adequate and optimal anti-diarrhea therapy at any DL and judged to be possibly or probably related to the trial treatment by the Investigator and/or the Sponsor.

Time frame:
Baseline Up to Day 29 of Cycle 1
Reported as:
Number · subjects
Part 1: Number of Subjects With Dose Limiting Toxicities (DLTs)
subjectsRegimen 1 (Part 1)Regimen 2 (Part 1)Regimen 3 (Part 1)
Part 1: Number of Subjects With Dose Limiting Toxicities (DLTs)105
PrimaryPart 2: Percentage of Subjects With Best Overall Response

The best overall response was to be reported as either of the following: (1) Morphologic complete remission (CR) = normalization of the peripheral blood absolute neutrophil count (PBANC) \>1.0x10\^9 per liter (/L), platelets \>100x10\^9 /L, bone marrow aspirate with less than or equal to (\<=) 5 percent (%) blasts, no blasts with Auer rods (AML only). (2) Complete remission with incomplete blood count recovery (CRi) = Same as CR without normalization of PBANC and platelet count. (3) Partial remission (PR) = normalization of PBANC \>1.0x10\^9/L, platelets \>100x10\^9/L, and at least a 50% decrease in the percentage of marrow aspirate blasts to 5-25%, or marrow blasts less than (\<) 5%. (4) Progressive disease (PD) = \>50% increase in peripheral blood or bone marrow blasts. (5) Stable disease (SD) = subjects who failed to achieve CR, CRi or PR and without criteria for PD.

Time frame:
Day 29 of every 29-day cycle until progression reported between day of first subject randomized, September 2009, until cut-off date, December 2012

No measurements were reported for this outcome.

SecondaryPart 1: Number of Subjects With Treatment-emergent Adverse Events (TEAEs), Serious TEAEs, TEAEs Leading to Death and TEAEs Leading to Permanent Treatment Discontinuation

An adverse event (AE) was defined as any new untoward medical occurrences/worsening of pre-existing medical condition, whether or not related to study drug. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect. TEAEs include both SAEs and non-SAEs.

Time frame:
Baseline up to 3 years
Reported as:
Number · Subjects
Part 1: Number of Subjects With Treatment-emergent Adverse Events (TEAEs), Serious TEAEs, TEAEs Leading to Death and TEAEs Leading to Permanent Treatment Discontinuation
SubjectsRegimen 1 (Part 1)Regimen 2 (Part 1)Regimen 3 (Part 1)
TEAEs333215
Serious TEAEs242812
TEAEs Leading to Death665
TEAEs Leading to Treatment Discontinuation777
SecondaryPart 1: Maximum Plasma Concentration (Cmax) of Pimasertib Single Dose
Time frame:
Predose 0.5, 1.0, 1.5, 2.0, 2.5, 4.0, 6.0, and 10.0 hours post-dose on Day 1 of cycle 1; Regimen 1, 2 and 3
Reported as:
Geometric mean · nanogram/milliliter
Part 1: Maximum Plasma Concentration (Cmax) of Pimasertib Single Dose
nanogram/milliliterPimasertib 8 mg (All Regimens [Part 1])Pimasertib 15 mg (All Regimens [Part 1])Pimasertib 23 mg (All Regimens [Part 1])Pimasertib 30 mg (All Regimens [Part 1])Pimasertib 42 mg (All Regimens [Part 1])Pimasertib 45 mg (All Regimens [Part 1])Pimasertib 60 mg (All Regimens [Part 1])Pimasertib 75 mg (All Regimens [Part 1])Pimasertib 90 mg (All Regimens [Part 1])
Part 1: Maximum Plasma Concentration (Cmax) of Pimasertib Single Dose14.8 ± 43.029.3 ± 32.059.1 ± 86.2132.8 ± 29.6151.6 ± 38.8207.0 ± 27.8269.9 ± 46.1241.9 ± 81.0342.6 ± 18.5
SecondaryPart 1: Maximum Plasma Concentration (Cmax) of Pimasertib Multiple Dose
Time frame:
Pre dose 0.5, 1.0, 1.5, 2.0, 2.5, 4.0, 6.0, and 10.0 hours post dose in Cycle 1 on Day 19 to Day 21 (Regimen 1 and 2) or Day 26 (Regimen 3).
Reported as:
Geometric mean · nanogram/milliliter
Part 1: Maximum Plasma Concentration (Cmax) of Pimasertib Multiple Dose
nanogram/milliliterPimasertib 8 mg (All Regimens [Part 1])Pimasertib 15 mg (All Regimens [Part 1])Pimasertib 23 mg (All Regimens [Part 1])Pimasertib 30 mg (All Regimens [Part 1])Pimasertib 42 mg (All Regimens [Part 1])Pimasertib 45 mg (All Regimens [Part 1])Pimasertib 60 mg (All Regimens [Part 1])Pimasertib 75 mg (All Regimens [Part 1])Pimasertib 90 mg (All Regimens [Part 1])
Part 1: Maximum Plasma Concentration (Cmax) of Pimasertib Multiple Dose23.6 ± 40.159.3 ± 53.169.6 ± 39.2150.1 ± 63.7187.8 ± 25.3123.2 ± 63.4231.4 ± 48.2383.2 ± 57.6486.3 ± NA
SecondaryPart 1: Time to Reach Maximum Plasma Concentration (Tmax): Single Dose
Time frame:
Predose 0.5, 1.0, 1.5, 2.0, 2.5, 4.0, 6.0, and 10.0 hours post-dose on Day 1 of cycle 1; Regimen 1, 2 and 3
Reported as:
Geometric mean · hour
Part 1: Time to Reach Maximum Plasma Concentration (Tmax): Single Dose
hourPimasertib 8 mg (All Regimens [Part 1])Pimasertib 15 mg (All Regimens [Part 1])Pimasertib 23 mg (All Regimens [Part 1])Pimasertib 30 mg (All Regimens [Part 1])Pimasertib 42 mg (All Regimens [Part 1])Pimasertib 45 mg (All Regimens [Part 1])Pimasertib 60 mg (All Regimens [Part 1])Pimasertib 75 mg (All Regimens [Part 1])Pimasertib 90 mg (All Regimens [Part 1])
Part 1: Time to Reach Maximum Plasma Concentration (Tmax): Single Dose0.94 ± 41.182.25 ± 53.201.56 ± 151.731.09 ± 38.741.11 ± 78.051.12 ± 19.621.03 ± 40.272.70 ± 96.841.17 ± 76.62
SecondaryPart 1: Time to Reach Maximum Plasma Concentration (Tmax): Multiple Dose
Time frame:
Pre dose 0.5, 1.0, 1.5, 2.0, 2.5, 4.0, 6.0, and 10.0 hours post dose in Cycle 1 on Day 19 to Day 21 (Regimen 1 and 2) or Day 26 (Regimen 3)
Reported as:
Geometric mean · hour
Part 1: Time to Reach Maximum Plasma Concentration (Tmax): Multiple Dose
hourPimasertib 8 mg (All Regimens [Part 1])Pimasertib 15 mg (All Regimens [Part 1])Pimasertib 23 mg (All Regimens [Part 1])Pimasertib 30 mg (All Regimens [Part 1])Pimasertib 42 mg (All Regimens [Part 1])Pimasertib 45 mg (All Regimens [Part 1])Pimasertib 60 mg (All Regimens [Part 1])Pimasertib 75 mg (All Regimens [Part 1])Pimasertib 90 mg (All Regimens [Part 1])
Part 1: Time to Reach Maximum Plasma Concentration (Tmax): Multiple Dose1.44 ± 78.611.75 ± 83.122.03 ± 59.041.99 ± 70.401.64 ± 73.931.41 ± 52.111.78 ± 112.592.75 ± 21.832.00 ± NA
SecondaryPart 1: Apparent Terminal Half-Life (t1/2) of Pimasertib: Single Dose

The apparent terminal half-life was defined as the time required for the plasma concentration of drug to decrease 50% in the final stage of its elimination.

Time frame:
Predose 0.5, 1.0, 1.5, 2.0, 2.5, 4.0, 6.0, and 10.0 hours post-dose on Day 1 of cycle 1; Regimen 1, 2 and 3
Reported as:
Geometric mean · hour
Part 1: Apparent Terminal Half-Life (t1/2) of Pimasertib: Single Dose
hourPimasertib 8 mg (All Regimens [Part 1])Pimasertib 15 mg (All Regimens [Part 1])Pimasertib 23 mg (All Regimens [Part 1])Pimasertib 30 mg (All Regimens [Part 1])Pimasertib 42 mg (All Regimens [Part 1])Pimasertib 45 mg (All Regimens [Part 1])Pimasertib 60 mg (All Regimens [Part 1])Pimasertib 75 mg (All Regimens [Part 1])Pimasertib 90 mg (All Regimens [Part 1])
Part 1: Apparent Terminal Half-Life (t1/2) of Pimasertib: Single Dose5.28 ± 41.553.52 ± 19.753.05 ± 13.964.01 ± 36.613.88 ± 42.263.45 ± 23.802.97 ± 21.924.21 ± 92.043.39 ± 49.59
SecondaryPart 1: Apparent Terminal Half-Life (t1/2) of Pimasertib: Multiple Dose

The apparent terminal half-life was defined as the time required for the plasma concentration of drug to decrease 50% in the final stage of its elimination.

Time frame:
Pre dose 0.5, 1.0, 1.5, 2.0, 2.5, 4.0, 6.0, and 10.0 hours post dose in Cycle 1 on Day 19 to Day 21 (Regimen 1 and 2) or Day 26 (Regimen 3).
Reported as:
Geometric mean · hour
Part 1: Apparent Terminal Half-Life (t1/2) of Pimasertib: Multiple Dose
hourPimasertib 8 mg (All Regimens [Part 1])Pimasertib 15 mg (All Regimens [Part 1])Pimasertib 23 mg (All Regimens [Part 1])Pimasertib 30 mg (All Regimens [Part 1])Pimasertib 42 mg (All Regimens [Part 1])Pimasertib 45 mg (All Regimens [Part 1])Pimasertib 60 mg (All Regimens [Part 1])Pimasertib 75 mg (All Regimens [Part 1])Pimasertib 90 mg (All Regimens [Part 1])
Part 1: Apparent Terminal Half-Life (t1/2) of Pimasertib: Multiple Dose6.97 ± 75.4710.91 ± 590.543.69 ± 22.693.93 ± 32.173.71 ± 21.383.96 ± 17.244.52 ± 66.998.44 ± 175.105.04 ± NA
SecondaryPart 1: Area Under Curve From Time Zero to Last Sampling Time at Which the Concentration is at or Above Lower Limit of Quantification (AUC0-t) of Pimasertib: Single Dose
Time frame:
Predose 0.5, 1.0, 1.5, 2.0, 2.5, 4.0, 6.0, and 10.0 hours post-dose on Day 1 of cycle 1; Regimen 1, 2 and 3
Reported as:
Geometric mean · hour*nanogram/milliliter
Part 1: Area Under Curve From Time Zero to Last Sampling Time at Which the Concentration is at or Above Lower Limit of Quantification (AUC0-t) of Pimasertib: Single Dose
hour*nanogram/milliliterPimasertib 8 mg (All Regimens [Part 1])Pimasertib 15 mg (All Regimens [Part 1])Pimasertib 23 mg (All Regimens [Part 1])Pimasertib 30 mg (All Regimens [Part 1])Pimasertib 42 mg (All Regimens [Part 1])Pimasertib 45 mg (All Regimens [Part 1])Pimasertib 60 mg (All Regimens [Part 1])Pimasertib 75 mg (All Regimens [Part 1])Pimasertib 90 mg (All Regimens [Part 1])
Part 1: Area Under Curve From Time Zero to Last Sampling Time at Which the Concentration is at or Above Lower Limit of Quantification (AUC0-t) of Pimasertib: Single Dose54.0 ± 57.2125.4 ± 42.4230.9 ± 60.9456.2 ± 25.5581.8 ± 45.4735.2 ± 47.2863.8 ± 52.8905.0 ± 92.81268.2 ± 31.9
SecondaryPart 1: Area Under Curve From Time Zero to Last Sampling Time at Which the Concentration is at or Above Lower Limit of Quantification (AUC0-t) of Pimasertib: Multiple Dose
Time frame:
Pre dose 0.5, 1.0, 1.5, 2.0, 2.5, 4.0, 6.0, and 10.0 hours post dose in Cycle 1 on Day 19 to Day 21 (Regimen 1 and 2) or Day 26 (Regimen 3).
Reported as:
Geometric mean · hour*nanogram/milliliter
Part 1: Area Under Curve From Time Zero to Last Sampling Time at Which the Concentration is at or Above Lower Limit of Quantification (AUC0-t) of Pimasertib: Multiple Dose
hour*nanogram/milliliterPimasertib 8 mg (All Regimens [Part 1])Pimasertib 15 mg (All Regimens [Part 1])Pimasertib 23 mg (All Regimens [Part 1])Pimasertib 30 mg (All Regimens [Part 1])Pimasertib 42 mg (All Regimens [Part 1])Pimasertib 45 mg (All Regimens [Part 1])Pimasertib 60 mg (All Regimens [Part 1])Pimasertib 75 mg (All Regimens [Part 1])Pimasertib 90 mg (All Regimens [Part 1])
Part 1: Area Under Curve From Time Zero to Last Sampling Time at Which the Concentration is at or Above Lower Limit of Quantification (AUC0-t) of Pimasertib: Multiple Dose131.4 ± 45.5307.2 ± 75.4321.9 ± 29.9679.4 ± 53.7761.2 ± 35.5628.0 ± 28.2991.6 ± 66.12195.2 ± 97.32144.7 ± NA
SecondaryPart 1: Area Under Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Pimasertib: Single Dose

The AUC0-inf was estimated by determining the total area under the curve of the concentration versus time curve extrapolated to infinity. It is obtained from AUC0-t plus AUCt-infinity.

Time frame:
Predose 0.5, 1.0, 1.5, 2.0, 2.5, 4.0, 6.0, and 10.0 hours post-dose on Day 1 of cycle 1; Regimen 1, 2 and 3
Reported as:
Geometric mean · hour*nanogram/milliliter
Part 1: Area Under Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Pimasertib: Single Dose
hour*nanogram/milliliterPimasertib 8 mg (All Regimens [Part 1])Pimasertib 15 mg (All Regimens [Part 1])Pimasertib 23 mg (All Regimens [Part 1])Pimasertib 30 mg (All Regimens [Part 1])Pimasertib 42 mg (All Regimens [Part 1])Pimasertib 45 mg (All Regimens [Part 1])Pimasertib 60 mg (All Regimens [Part 1])Pimasertib 75 mg (All Regimens [Part 1])Pimasertib 90 mg (All Regimens [Part 1])
Part 1: Area Under Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Pimasertib: Single Dose80.5 ± 52.9145.2 ± 42.1315.6 ± 76.3562.1 ± 33.3734.9 ± 49.7858.4 ± 49.61027.4 ± 49.21530.7 ± 135.31873.9 ± 68.8
SecondaryPart 1: Area Under Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Pimasertib: Multiple Dose

The AUC0-inf was estimated by determining the total area under the curve of the concentration versus time curve extrapolated to infinity. It is obtained from AUC0-t plus AUCt-infinity.

Time frame:
Pre dose 0.5, 1.0, 1.5, 2.0, 2.5, 4.0, 6.0, and 10.0 hours post dose in Cycle 1 on Day 19 to Day 21 (Regimen 1 and 2) or Day 26 (Regimen 3)
Reported as:
Geometric mean · hour*nanogram/milliliter
Part 1: Area Under Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Pimasertib: Multiple Dose
hour*nanogram/milliliterPimasertib 8 mg (All Regimens [Part 1])Pimasertib 15 mg (All Regimens [Part 1])Pimasertib 23 mg (All Regimens [Part 1])Pimasertib 30 mg (All Regimens [Part 1])Pimasertib 42 mg (All Regimens [Part 1])Pimasertib 45 mg (All Regimens [Part 1])Pimasertib 60 mg (All Regimens [Part 1])Pimasertib 75 mg (All Regimens [Part 1])Pimasertib 90 mg (All Regimens [Part 1])
Part 1: Area Under Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Pimasertib: Multiple Dose226.2 ± 91.0789.3 ± 1038.0451.2 ± 39.41030.2 ± 51.6938.0 ± 46.6786.7 ± 21.21270.8 ± 104.32712.6 ± 456.72830.7 ± NA
SecondaryPart 1: Apparent Oral Clearance (CL/f) of Pimasertib: Single Dose

Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Apparent clearance after oral dose (CL/f) is influenced by the fraction absorbed. Data for Pimasertib 75 mg arm was not available for all the regimens combined, thus reported as separate outcome measure and not included in this outcome.

Time frame:
Predose 0.5, 1.0, 1.5, 2.0, 2.5, 4.0, 6.0, and 10.0 hours post-dose on Day 1 of cycle 1; Regimen 1, 2 and 3
Reported as:
Geometric mean · liter/hour
Part 1: Apparent Oral Clearance (CL/f) of Pimasertib: Single Dose
liter/hourPimasertib 8 mg (All Regimens [Part 1])Pimasertib 15 mg (All Regimens [Part 1])Pimasertib 23 mg (All Regimens [Part 1])Pimasertib 30 mg (All Regimens [Part 1])Pimasertib 42 mg (All Regimens [Part 1])Pimasertib 45 mg (All Regimens [Part 1])Pimasertib 60 mg (All Regimens [Part 1])Pimasertib 90 mg (All Regimens [Part 1])
Part 1: Apparent Oral Clearance (CL/f) of Pimasertib: Single Dose99.43 ± 52.86103.29 ± 42.0772.88 ± 76.2853.37 ± 33.2657.15 ± 49.7252.42 ± 49.5958.40 ± 49.2148.03 ± 68.78
SecondaryPart 1: Apparent Oral Clearance (CL/f) of Pimasertib for Pimasertib 75 mg Reporting Arm: Single Dose

Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Apparent clearance after oral dose (CL/f) is influenced by the fraction absorbed.

Time frame:
Predose 0.5, 1.0, 1.5, 2.0, 2.5, 4.0, 6.0, and 10.0 hours post-dose on Day 1 of cycle 1; Regimen 1, 2 and 3
Reported as:
Mean · liter/hour
Part 1: Apparent Oral Clearance (CL/f) of Pimasertib for Pimasertib 75 mg Reporting Arm: Single Dose
liter/hourPimasertib 75 mg (All Regimens [Part 1])
Regimen 1 (n=0)NA ± NA
Regimen 2 (n=3)93 ± 103.367
Regimen 3 (n=1)45 ± NA
SecondaryPart 1: Apparent Oral Clearance (CL/f) of Pimasertib: Multiple Dose

Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Apparent clearance after oral dose (CL/f) is influenced by the fraction absorbed.

Time frame:
Pre dose 0.5, 1.0, 1.5, 2.0, 2.5, 4.0, 6.0, and 10.0 hours post dose in Cycle 1 on Day 19 to Day 21 (Regimen 1 and 2) or Day 26 (Regimen 3)
Reported as:
Geometric mean · liter/hour
Part 1: Apparent Oral Clearance (CL/f) of Pimasertib: Multiple Dose
liter/hourPimasertib 8 mg (All Regimens [Part 1])Pimasertib 15 mg (All Regimens [Part 1])Pimasertib 23 mg (All Regimens [Part 1])Pimasertib 30 mg (All Regimens [Part 1])Pimasertib 42 mg (All Regimens [Part 1])Pimasertib 45 mg (All Regimens [Part 1])Pimasertib 60 mg (All Regimens [Part 1])Pimasertib 75 mg (All Regimens [Part 1])Pimasertib 90 mg (All Regimens [Part 1])
Part 1: Apparent Oral Clearance (CL/f) of Pimasertib: Multiple Dose60.90 ± 45.5146.74 ± 78.8566.52 ± 33.4037.95 ± 47.5955.80 ± 35.9069.23 ± 33.4065.11 ± 65.6934.44 ± 119.5141.96 ± NA
SecondaryPart 1: Apparent Oral Volume of Distribution (Vz/f) of Pimasertib:Single Dose

Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. Apparent volume of distribution after oral dose (Vz/f) was influenced by the fraction absorbed. Data for Pimasertib 75 mg arm was not available for all the regimens combined, thus reported as separate outcome measure and not included in this outcome.

Time frame:
Predose 0.5, 1.0, 1.5, 2.0, 2.5, 4.0, 6.0, and 10.0 hours post-dose on Day 1 of cycle 1; Regimen 1, 2 and 3
Reported as:
Geometric mean · liter
Part 1: Apparent Oral Volume of Distribution (Vz/f) of Pimasertib:Single Dose
literPimasertib 8 mg (All Regimens [Part 1])Pimasertib 15 mg (All Regimens [Part 1])Pimasertib 23 mg (All Regimens [Part 1])Pimasertib 30 mg (All Regimens [Part 1])Pimasertib 42 mg (All Regimens [Part 1])Pimasertib 45 mg (All Regimens [Part 1])Pimasertib 60 mg (All Regimens [Part 1])Pimasertib 90 mg (All Regimens [Part 1])
Part 1: Apparent Oral Volume of Distribution (Vz/f) of Pimasertib:Single Dose757.5 ± 48.3524.8 ± 51.5320.8 ± 60.1308.8 ± 27.1320.2 ± 40.4260.8 ± 46.9250.3 ± 48.5235.2 ± 24.2
SecondaryPart 1: Apparent Oral Volume of Distribution (Vz/f) of Pimasertib for Pimasertib 75 mg Reporting Arm:Single Dose

Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. Apparent volume of distribution after oral dose (Vz/f) was influenced by the fraction absorbed.

Time frame:
Predose 0.5, 1.0, 1.5, 2.0, 2.5, 4.0, 6.0, and 10.0 hours post-dose on Day 1 of cycle 1; Regimen 1, 2 and 3
Reported as:
Mean · liter
Part 1: Apparent Oral Volume of Distribution (Vz/f) of Pimasertib for Pimasertib 75 mg Reporting Arm:Single Dose
literPimasertib 75 mg (All Regimens [Part 1])
Regimen 1 (n = 0)NA ± NA
Regimen 2 (n = 3)442.2 ± 214.6
Regimen 3 (n = 1)196.0 ± NA
SecondaryPart 1: Apparent Oral Volume of Distribution (Vz/f) of Pimasertib: Multiple Dose

Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. Apparent volume of distribution after oral dose (Vz/f) was influenced by the fraction absorbed.

Time frame:
Pre dose 0.5, 1.0, 1.5, 2.0, 2.5, 4.0, 6.0, and 10.0 hours post dose in Cycle 1 on Day 19 to Day 21 (Regimen 1 and 2) or Day 26 (Regimen 3)
Reported as:
Geometric mean · liter
Part 1: Apparent Oral Volume of Distribution (Vz/f) of Pimasertib: Multiple Dose
literPimasertib 8 mg (All Regimens [Part 1])Pimasertib 15 mg (All Regimens [Part 1])Pimasertib 23 mg (All Regimens [Part 1])Pimasertib 30 mg (All Regimens [Part 1])Pimasertib 42 mg (All Regimens [Part 1])Pimasertib 45 mg (All Regimens [Part 1])Pimasertib 60 mg (All Regimens [Part 1])Pimasertib 75 mg (All Regimens [Part 1])Pimasertib 90 mg (All Regimens [Part 1])
Part 1: Apparent Oral Volume of Distribution (Vz/f) of Pimasertib: Multiple Dose601.7 ± 79.2863.7 ± 193.5332.8 ± 14.5207.8 ± 46.8293.1 ± 27.6395.1 ± 52.9422.0 ± 79.2689.9 ± 16.0305.2 ± NA
SecondaryPart 1: Percentage of Subjects With Best Overall Response

The best overall response was reported as either of the following: (1) Morphologic complete remission (CR) = normalization of the peripheral blood absolute neutrophil count (PBANC) \>1.0x10\^9 per liter (/L), platelets \>100x10\^9 /L, bone marrow aspirate with less than or equal to (\<=) 5 percent (%) blasts, no blasts with Auer rods (AML only). (2) Complete remission with incomplete blood count recovery (CRi) = Same as CR without normalization of PBANC and platelet count. (3) Partial remission (PR) = normalization of PBANC \>1.0x10\^9/L, platelets \>100x10\^9/L, and at least a 50% decrease in the percentage of marrow aspirate blasts to 5-25%, or marrow blasts less than (\<) 5%. (4) Progressive disease (PD) = \>50% increase in peripheral blood or bone marrow blasts. (5) Stable disease (SD) = Subjects who failed to achieve CR, CRi or PR and without criteria for PD.

Time frame:
Day 29 of every alternate 29-day cycle until progression reported between day of first subject randomized, September 2009, until cut-off date, December 2012
Reported as:
Number · Percentage of Subjects
Part 1: Percentage of Subjects With Best Overall Response
Percentage of SubjectsRegimen 1 (Part 1)Regimen 2 (Part 1)Regimen 3 (Part 1)
CR0.00.00.0
CRi0.00.00.0
PR0.00.00.0
SD60.077.371.4
PD40.022.728.6
SecondaryPart 2: Number of Subjects With TEAEs, Serious TEAEs, TEAEs Leading to Death and TEAEs Leading to Permanent Treatment Discontinuation

An adverse event (AE) was defined as any new untoward medical occurrences/worsening of pre-existing medical condition, whether or not related to study drug. A serious adverse event (SAE) was an AE that results in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect.

Time frame:
Up to 3 years

No measurements were reported for this outcome.

Adverse events

Collected over Up to 3 years. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Regimen 1 (Part 1)—24/33 (72.7%)32/33 (97%)
Regimen 2 (Part 1)—28/32 (87.5%)30/32 (93.8%)
Regimen 3 (Part 1)—12/15 (80%)15/15 (100%)
Most frequent serious events
Showing 10 of 91
Most frequent serious events
EventRegimen 1 (Part 1)Regimen 2 (Part 1)Regimen 3 (Part 1)
Febrile NeutropeniaBlood and lymphatic system disorders4/339/322/15
PneumoniaInfections and infestations7/334/323/15
PyrexiaGeneral disorders1/335/321/15
DiarrhoeaGastrointestinal disorders2/332/322/15
Pleural EffusionRespiratory, thoracic and mediastinal disorders1/330/322/15
CellulitisInfections and infestations2/333/320/15
SepsisInfections and infestations2/333/321/15
EpistaxisRespiratory, thoracic and mediastinal disorders3/330/321/15
ThrombocytosisBlood and lymphatic system disorders0/330/321/15
Cardiac failure congestiveCardiac disorders1/330/321/15
Most frequent other events
Showing 10 of 244
Most frequent other events
EventRegimen 1 (Part 1)Regimen 2 (Part 1)Regimen 3 (Part 1)
DiarrhoeaGastrointestinal disorders14/3316/328/15
NauseaGastrointestinal disorders10/337/322/15
Oedema peripheralGeneral disorders6/338/324/15
HypocalcaemiaMetabolism and nutrition disorders1/332/324/15
RashSkin and subcutaneous tissue disorders4/336/324/15
PyrexiaGeneral disorders7/338/321/15
Aspartate aminotransferase increasedInvestigations8/337/323/15
DizzinessNervous system disorders7/335/322/15
HyperuricaemiaMetabolism and nutrition disorders2/333/323/15
HypoalbuminaemiaMetabolism and nutrition disorders1/332/323/15

Baseline characteristics

Baseline analysis population included all the subjects who were treated with at least one administration of pimasertib.

Age, Customized
Age, Customized(Subjects)Regimen 1 (Part 1)Regimen 2 (Part 1)Regimen 3 (Part 1)Total
18 to less than (<) 601412632
60 to <751316635
Greater than or equal to (>=) 7564313
Sex: Female, Male
Sex: Female, Male(Participants)Regimen 1 (Part 1)Regimen 2 (Part 1)Regimen 3 (Part 1)Total
Female913729
Male2419851
08

Study locations

9 sites
  • Northwestern University
    Chicago, Illinois, United States
  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    Baltimore, Maryland, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts, United States
  • University of Texas - MD Anderson Cancer Center
    Houston, Texas, United States
  • Hospital Hotel Dieu, Service D'Hematologie
    Nantes, Cedex, France
  • Hospital Edouard Herriot, Service d'Hematologie Clinique
    Lyon Cedex, France
  • Hospital Saint Louis, Service des Maladies du Sang
    Paris, France
  • CHU du Haut-Leveque, Service des Maladies du Sang Unite de Recherche Clinique
    Pessac, France
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2009 to primary completion in Dec 2012, 39 months.

Results were first posted in Mar 2017, 4 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 11, 2009
First posted
Aug 12, 2009
StartActual
Sep 30, 2009
Primary completionActual
Dec 31, 2012
CompletionActual
Dec 31, 2012
Results first posted
Mar 29, 2017
Last update
Aug 21, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00957580
Lead sponsor
EMD Serono
Responsible party
Sponsor
First posted
Aug 12, 2009
Start date
Sep 30, 2009
Primary completion
Dec 31, 2012
Completion
Dec 31, 2012
Results posted
Mar 29, 2017
Last update
Aug 21, 2017

Study contacts

Medical responsible
study director · Merck KGaA, Darmstadt, Germany

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pimasertib

Start the discussion